Dr. Declan G. Murphy discusses results from the phase 3 proPSMA study of Ga 68 PSMA-11 in patients with high-risk prostate cancer.
In December 2020, the FDA approved Gallium (Ga) 68 PSMA-1 as the first drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
Declan G. Murphy, MBBCh, was the senior author of the phase 3 proPSMA study, which examined Ga 68 PSMA-1 in patients with high-risk prostate cancer before curative-intent surgery. The study randomized 152 men to conventional imaging and 150 men to Ga 68 PSMA-1 between March 22, 2017, and November 2, 2018. In this video, Murphy discusses the results of the study.
Eighty-seven (30%) of 295 men with available follow-up data had pelvic nodal or distant metastatic disease. The accuracy rate of PSMA PET-CT was 27% greater than the accuracy rate of conventional imaging, at 92% versus 65%, respectively (P <.0001). Sensitivity (85% vs 38%) and specificity (98% vs 91%) was also improved with PSMA PET-CT over conventional imaging.
PSMA PET-CT also conferred management changes more frequently (41 vs 23 men). Additionally, 23% of the findings with conventional management were equivocal compared with only 7% with PSMA PET-CT.
“PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning,” Murphy and coauthors wrote in their study conclusion (Lancet. 2020;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7).
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Blue light cystoscopy decreases risk of recurrence, progression in NMIBC
May 9th 2024“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.